Kala Bio Earnings Reports

Kala Bio ended Q2 2025 with a net loss of $11.2 million and completed enrollment in its KPI-012 Phase 2b CHASE trial for PCED, with topline results expected in September. Cash reserves decreased but remain sufficient into Q1 2026.

KALA BIO reported a net loss of $8.2 million for Q4 2024, an improvement from $8.6 million in Q4 2023. The company also announced a private placement financing of $10.75 million, extending its cash runway into Q1 2026.

KALA BIO reported a net loss of $9.0 million, or $1.93 per share, for the third quarter ended September 30, 2024. The company had cash and cash equivalents of $49.2 million as of September 30, 2024.

KALA BIO reported a net loss of $9.6 million for the second quarter of 2024. The company's cash and cash equivalents were $54.2 million as of June 30, 2024, which is expected to fund operations into the fourth quarter of 2025.

Kala Bio reported a net loss of $11.8 million for the first quarter of 2024, with cash and cash equivalents totaling $48.5 million as of March 31, 2024. The company is focused on advancing its clinical program for KPI-012 in PCED and exploring its platform technology for other corneal and retinal diseases.

KALA BIO reported a net loss of $8.6 million for Q4 2023, compared to a net loss of $12.8 million for the same period in 2022. Research and development expenses increased to $4.7 million due to higher KPI-012 development costs. Cash and cash equivalents totaled $50.9 million as of December 31, 2023.

KALA BIO reported a net loss of $8.7 million for the third quarter of 2023, with research and development expenses at $5.6 million and selling, general and administrative expenses at $5.0 million. The company's cash and cash equivalents totaled $56.1 million as of September 30, 2023, expected to fund operations into the second quarter of 2025.

KALA BIO reported a net loss of $10.4 million for the second quarter of 2023. The company's cash, cash equivalents, and short-term investments totaled $59.2 million as of June 30, 2023. A $15 million grant was awarded by the California Institute for Regenerative Medicine (CIRM) to support the KPI-012 program.

Kala Pharmaceuticals reported a net loss of $14.5 million for the first quarter of 2023, with no product revenues due to the sale of its commercial portfolio. The company's cash and cash equivalents totaled $63.6 million. Kala is focused on advancing KPI-012 for PCED treatment and received a $15 million grant from CIRM to support this program.

Kala Pharmaceuticals reported a net loss of $12.8 million for Q4 2022, with no product revenues recognized following the sale of its commercial portfolio to Alcon. The company closed a $31.0 million private placement financing in December 2022 and is advancing its KPI-012 program for persistent corneal epithelial defect (PCED).

Kala Pharmaceuticals reported a net income of $29.1 million for the third quarter of 2022, which includes a gain on the sale of its commercial business to Alcon of $47.0 million. The company's cash and cash equivalents were $52.4 million as of September 30, 2022, expected to fund operations into Q2 2024. Kala plans to initiate a Phase 2/3 clinical trial of KPI-012 in PCED patients in the fourth quarter of 2022.

Kala Pharmaceuticals reported a net loss of $28.1 million, or $0.38 per share, for the quarter ended June 30, 2022. Kala completed the sale of EYSUVIS and INVELTYS to Alcon Inc. for an upfront payment of $60 million. Kala plans to initiate a Phase 2/3 clinical trial of KPI-012 in PCED patients in the fourth quarter of 2022.

Kala Pharmaceuticals reported net product revenues of $1.4 million for the quarter ended March 31, 2022, with $1.0 million from EYSUVIS sales and $0.4 million from INVELTYS sales. The company's cash, cash equivalents, and short-term investments were $70.2 million as of March 31, 2022.

Kala Pharmaceuticals reported Q4 2021 net product revenues of $1.9 million, with EYSUVIS sales at $1.2 million and INVELTYS sales at $0.7 million. The company had cash and cash equivalents of $92.1 million as of December 31, 2021.

Kala Pharmaceuticals reported a net product revenue of $3.1 million for the third quarter of 2021. EYSUVIS prescriptions increased by 19% compared to the second quarter of 2021. The company also acquired Combangio, expanding its clinical-stage pipeline.

Kala Pharmaceuticals reported net product revenues of $3.1 million for the quarter ended June 30, 2021. EYSUVIS prescriptions increased by 93% compared to the first quarter of 2021. The company expanded commercial coverage for EYSUVIS to more than 96 million lives.

Kala Pharmaceuticals reported net product revenues of $3.3 million for Q1 2021, with $1.64 million from EYSUVIS sales and $1.63 million from INVELTYS sales. The company's cash position was strong at $156.0 million, projecting a cash runway for at least two years. A new credit facility provides up to $125 million.

Kala Pharmaceuticals reported a net product revenue of $2.2 million for the quarter ended December 31, 2020, which includes $1.9 million from INVELTYS sales and $0.3 million from EYSUVIS sales. The company's cash, cash equivalents, and short-term investments totaled $153.5 million as of December 31, 2020 and anticipates that its cash resources as of December 31, 2020, together with anticipated INVELTYS revenue and the $18.2 million in net proceeds raised in January 2021 under the Company’s ATM offering program, will enable it to fund its operations into at least the fourth quarter of 2022.

Kala Pharmaceuticals reported a net product revenue of $2.2 million from INVELTYS sales. The company received FDA approval for EYSUVIS and anticipates shipping to wholesalers by the end of 2020. Kala expects its cash position and INVELTYS revenue to provide a runway into at least the third quarter of 2022, with EYSUVIS revenue expected to provide additional runway.

Kala Pharmaceuticals reported a net product revenue of $0.8 million for the second quarter ended June 30, 2020, related to INVELTYS sales, compared to $2.1 million in the second quarter of 2019. The FDA accepted Kala's NDA resubmission for EYSUVIS, with a PDUFA goal date of October 30, 2020. As of June 30, 2020, Kala had cash, cash equivalents, and short-term investments of $184.6 million.

Kala Pharmaceuticals reported a net product revenue of $1.1 million from INVELTYS sales, a decrease compared to the previous year. The company resubmitted the NDA for EYSUVIS to the FDA and anticipates a potential approval and launch by year-end. Kala's cash resources are expected to fund operations into at least the second quarter of 2022.

Kala Pharmaceuticals reported Q4 2019 financial results, with net product revenue of $1.2 million from INVELTYS sales. The company completed the last patient visit for the STRIDE 3 trial and anticipates topline results in Q1 2020.